Filed in archive
Corporate and Industrial News
by ruth on July 20, 2006
"Examining events on tap for the second half of 2006, we continue to see opportunities for positive risk-adjusted returns in selected large and small cap biotechnology stocks," said Steven Harr, a Morgan Stanley analyst.
Among Morgan Stanley's top picks were:
- MedImmune: Products include biopharmaceuticals for infectious diseases, oncology and immunology: Flumist®, Synagis®, Ethyol®, Cytogam®
- Genentech: Biopharma focusing on oncology, immunology, disorders of tissue growth and repair, including angiogenic disorders. CEO Arthur Levinson cited as top molecular millionaire. Latest from the pipeline: Lucentis, against neovascular age-related macular degenetration.
- Gilead Sciences: Develops biopharmaceuticals for the treatment of life-threatening infectious diseases such as HIV/AIDS, influenza, hepatitis, and severe fungal infections. Latest approved drug candidate: Atripla,a three-in-one tablet against HIV.
- and Celgene: Focuses on cancer and inflammatory disease therapeutics. Top products includeThalomid and Revlimid, both approved for the treatment of multiple myeloma, among others.
Read more about Morgan Stanley's report from the Forbes article.
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/29785
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for Morgan Stanley Expect Favorable Returns from Large Biotech Companies:
|
Rating: 7.67 out of 3 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
